Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab for T-cell Depletion in Mismatched Unrelated Donor Transplant
NCT00555048Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2007
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), sponsored by Fred Hutchinson Cancer Center. Started Sep 2007; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Beyond the preview
Go deeper on NCT00555048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555048.